Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in non-small cell lung cancer
- New trial
Non-small cell lung cancer
Phase II Trial of HLX43 (Anti-PD-L1 ADC) in Advanced NSCLC
Henlius is launching a global, open-label Phase II study to explore the optimal dosing and evaluate the efficacy, safety, and tolerability of HLX43 in patients with advanced/metastatic NSCLC, including those with…
NCT06907615 - New trial
Non-small cell lung cancer
A Phase I, Single-Arm, Single-Institution Study Evaluating Neoadjuvant Chemoimmunotherapy with Immunosensitizing Radiation for Borderline Resectable NSCLC
UMB is exploring whether adding three fractions of SBRT immediately before three cycles of chemoimmunotherapy with nivolumab can enhance surgical outcomes in borderline resectable NSCLC. Patients will be followed for…
NCT06800339 - New trial
Non-small cell lung cancer
Expanded Access Program of Taletrectinib in Advanced ROS1+ NSCLC
This expanded access program from Nuvation Bio provides taletrectinib—a ROS1 and NTRK inhibitor—for patients with advanced or metastatic ROS1-positive NSCLC who aren't candidates for approved therapies, allowing…
NCT06841874 - New trial
Non-small cell lung cancer
Phase 3 Trial of Ivonescimab vs Pembrolizumab in High PD-L1 Metastatic NSCLC
Summit Therapeutics is leading a multicenter, double-blind Phase 3 study comparing ivonescimab—a PD-1/VEGF bispecific antibody—with pembrolizumab in first-line therapy for metastatic NSCLC patients whose tumors…
NCT06767514 - Trial result
Non-small cell lung cancer
Zongertinib Delivers Robust Efficacy in Previously Treated HER2-Mutant NSCLC
In a phase 1a-1b multicohort trial, zongertinib, an oral, irreversible, HER2-selective tyrosine kinase inhibitor (TKI), demonstrated impressive activity in patients with previously treated HER2-mutant NSCLC. In…
- New trial
Non-small cell lung cancer
Phase 2 Trial: Subcutaneous Nivolumab with Ipilimumab and Chemotherapy in Untreated NSCLC
Bristol-Myers Squibb is evaluating two dosing regimens of subcutaneous nivolumab combined with intravenous ipilimumab and standard chemotherapy in patients with previously untreated metastatic or recurrent NSCLC to…
NCT06946797 - New trial
Non-small cell lung cancer
Phase II Study: Neoadjuvant Dual Checkpoint Blockade in Resectable NSCLC
Mayo Clinic is evaluating a fixed-dose combination of cemiplimab and fianlimab given neoadjuvantly in patients with stage IB–IIIB NSCLC, aiming to enhance preoperative tumor cell eradication and potentially improve…
NCT06918132 - New trial
Non-small cell lung cancer
Phase 1 Study: Dose Escalation of DZD6008 in EGFR-Mutant Advanced NSCLC
Dizal Pharmaceuticals is assessing DZD6008, an EGFR (brain-blood barrier positive) inhibitor, across multiple dose escalation cohorts to evaluate its safety, tolerability, pharmacokinetics, and antitumor efficacy in…
NCT06905197 - New trial
Non-small cell lung cancer
Phase 2 Study: ctDNA-Guided Neoadjuvant and Adjuvant Pembrolizumab in Early-Stage NSCLC
University of Miami is evaluating whether circulating tumor DNA (ctDNA) can predict response to neoadjuvant platinum-based chemotherapy and surgery, and guide adjuvant pembrolizumab treatment to prevent cancer…
NCT06902272 - Trial result
Non-small cell lung cancer
Perioperative CTC Changes Predict Early Relapse in Resectable NSCLC
In a study of 99 patients with resectable NSCLC stratified by lymph node status, specific perioperative shifts in circulating tumor cell counts were linked to disease-free survival. In early-stage cases (cohort…
- Trial result
Non-small cell lung cancer
Divarasib Plus Migoprotafib: A Dual-Target Strategy Showing Encouraging Efficacy in KRAS G12C NSCLC
In this phase I study, combination therapy with divarasib—a next-generation KRAS G12C inhibitor—and migoprotafib—a SHP2 inhibitor—demonstrated an acceptable safety profile and promising antitumor activity in KRAS…
- Trial result
Non-small cell lung cancer
Trop-2 Expression Uncoupled from Efficacy in SG + Pembrolizumab ± Carboplatin for mNSCLC
In EVOKE-02, metastatic NSCLC patients without actionable genomic alterations exhibited high Trop-2 levels, yet objective response rates and progression-free survival were similar regardless of whether tumor Trop-2…
- Trial result
Non-small cell lung cancer
D3S-001 Breaks Through Resistance in KRAS G12C Inhibitor-Resistant NSCLC
In a Phase 2 trial, D3S-001—a next-generation GDP-bound KRAS G12C inhibitor engineered for rapid and complete target engagement—was administered as monotherapy to 20 NSCLC patients who progressed on prior KRAS G12C…
- Trial result
Non-small cell lung cancer
Daraxonrasib Shows Promise in NSCLC: Early ctDNA Clearance Linked to Improved Outcomes
In this Phase 1 study of daraxonrasib for RAS G12X mutant NSCLC, paired plasma samples revealed that complete clearance of ctDNA by Day 1 of Cycle 2/3 was observed in 89% of responders and 70% of patients with stable…
- New trial
Non-small cell lung cancer
Phase II Trial Combines Photoimmunotherapy with Anti-PD1 in Advanced NSCLC
Roswell Park Cancer Institute is evaluating ASP-1929 photoimmunotherapy paired with cemiplimab in patients with refractory, inoperable, or metastatic stage IIIB–IV NSCLC. This study employs a targeted approach where…
NCT06943664
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.